LONDON, Ontario—Two studies recently published by the Journal of Functional Foods, sponsored by KGK Synergize Inc. (KGK), evaluated the safety and efficacy of Diabetinol™, a proprietary ingredient, in both an in vivo and a human clinical study (published online May 26, 2010). The results of the in vivo study demonstrated Diabetinol did not produce any adverse effects in a fructose-induced hamster model and showed improvement in blood glucose, insulin, cholesterol and triglycerides.
In a human clinical study conducted by SIBR Research Inc., the use of Diabetinol over a three-month period was safe and effective in significantly reducing glucose intolerance in subjects with impaired fasting glucose (IFG), who were also taking oral medication. Diabetinol significantly reduced total cholesterol, low-density lipoprotein (LDL) cholesterol, and decreasing trends in HbA1c were also observed. The data suggested Diabetinol as a natural food product may have protective effects in individuals with a combined IFG and hyperlipidemia.
Mal Evans, Ph.D., KGK’s scientific director, stated: “This study has demonstrated an important role for Diabetinol as a novel ingredient in glycemic control. Diabetinol may aid in the management of risk factors in subjects with IFG who are taking oral medication, two very exciting discoveries.”
